Introduction {#sec1}
============

Progress in the development of different chemotherapeutic agents has produced an enormous opportunity to fight against cancer for the past 2 decades.^[@ref1]^ Anthracycline, alkaloid, and inorganic metals are the front line compounds that are used in chemotherapy.^[@ref2]^ However, these small molecules suffer from nonspecific binding and poor aqueous solubility that limit their use in chemotherapy.^[@ref3]^ In recent years, nanocarriers have gained significant interest in nanomedicine.^[@ref4]^ Nanocarriers, including micelles, vesicles, liposomes, dendrimers, and polymer--drug conjugates, show promising activity against various cancers because of their ability to reach specific targeted sites.^[@ref5]−[@ref8]^

Among the different classes of chemotherapeutic agents, alkaloids show significant promising activity toward various cancers.^[@ref9]^ Camptothecin (CPT) is one of the alkaloid classes of chemotherapeutic agents, which is well-known for its anticancer activity toward various cancers via inhibiting the function of topoisomerase I, an essential enzyme for protein synthesis in the transcription process.^[@ref9]^ This drug was first isolated by Wall and Wani from the bark of *Camptotheca acuminata* in 1960, and the anticancer therapeutic activity was well-explored by different research groups later on.^[@ref10],[@ref11]^ However, despite its promising anticancer activity toward various cancers, this small molecule suffers from stability and aqueous solubility, which limit its use in conventional cancer therapy in the biological system, for example, through oral administration or intravenous injection.^[@ref12]^ Several efforts have been made by different research groups to address the problems associated with this small molecule by making different functional derivatives, but none of them show any promising activity because of the lack of site-specificity that causes adverse side effects.^[@ref13]^

Recently, a polymer-based nanotheranostic system has become an emerging class of compounds that simultaneously integrates therapy and diagnosis.^[@ref14]^ Among different systems, the use of a polymer-based drug-delivery vehicle has become prominent over all other existing systems because of its pharmacokinetics and biodistribution profile via the enhanced permeability and retention (EPR) effect and the capability of maintaining the therapeutic concentration over a longer period of time.^[@ref15]^ Hence, this theranostic medicine, which is capable of assistance in diagnosis and monitoring the therapeutic response, plays a significant role in the era of personalized medicine.

Among several diagnostic techniques, magnetic resonance imaging (MRI) has gained significant attention because of its noninvasive nature.^[@ref16]^ This modern technique employs MRI contrast agents that help change the relaxation behavior of the targeted nuclei present in the tissues. Of the various relaxation mechanisms, transverse relaxation is frequently employed to exploit the advantages of contrast imaging.^[@ref16]^ Toward this goal, different literature studies have reported different types of nanocarriers that carry the magnetic particles along with drug molecules, but the noncovalent attachment or the encapsulation of these inorganic magnetic particles leads to poor aqueous solubility, which causes severe side effects. The poor aqueous solubility also causes the lower contrast efficiency because the water molecules have poor access to the magnetic core;^[@ref17]^ hence, there is a pressing need to have a covalent-attached magnetic nanocarrier that can lead to a highly water-soluble nanotheranostic system.

To reduce the adverse cytotoxic effect of the chemotherapeutic agent, researchers have been trying to modify the system by incorporating different pendent functionalities into the prodrug system to make it more site-specific.^[@ref3],[@ref4],[@ref6]^ Basically, target specificity deals with those kind of molecules that are required for a cell to grow. Now, for the rapid growth of a cancerous cell, high uptake value of some specific vitamins leads to the expression of receptors on the cancer cell surface in high amounts, when compared with a normal cell surface. Therefore, functionalization of this kind of molecules (folate, biotin, fructose) can guide the chemotherapeutic agent toward the cancer cells more site-specifically, which reduces the side effects.^[@ref18]−[@ref20]^

In this work, we report the development of a nanotheranostic agent capable of sustained delivery of CPT and MRI because of the presence of a superparamagnetic norbornene cobalt unit. The attachment of cobalt carbonyl to the acetylene functionalized norbornene by Nicholas reaction at the monomeric level.^[@ref22]^ The NMR one-dimensional (1D) image shows a very prominent effect on the transverse relaxation of water molecules in micromolar concentration. This nanotheranostic agent is further modified by poly(ethylene glycol)--biotin (PEG--biotin), which helps the nanocarrier become site-specific.^[@ref21]^ This highly water-soluble functional polymer nanocarrier is expected to be useful in theranostics.

Results and Discussion {#sec2}
======================

Toward the goal of making a norbornene-based theranostic prodrug, three different monomers have been designed (**Mono 1--3**) and synthesized as shown in [Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}. The formation of all monomers was confirmed by ^1^H NMR and ^13^C NMR spectroscopy ([Figures S1--S14](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). To synthesize **Mono 1**, we first prepared the propargyl-attached norbornene (**2**), where the propargyl proton signal appeared. ^1^H NMR spectrum at δ = 2.1 ppm in CDCl~3~ ([Figure S3](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)) and the formation of the product was further confirmed by ^13^C NMR spectroscopy ([Figure S4](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The attachment of cobalt carbonyl to the propargyl moiety was confirmed by NMR spectroscopy. In the ^1^H NMR spectrum, the shifting of the signal at δ = 6.0 ppm from 2.1 ppm confirmed the attachment of cobalt carbonyl to the terminal alkyne group ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a).^[@ref22],[@ref26]^

![(a,b) ^1^H NMR spectrum of **Mono 1--2**.](ao-2017-00221k_0001){#fig1}

![Synthesis of **Mono 1--3**](ao-2017-00221k_0010){#sch1}

Reaction Scheme {#sec3}
===============

The ^13^C NMR spectrum clearly supported the formation of a product as a new peak arose at δ = 200 ppm corresponding to Co--CO ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The synthesis of **Mono 2** was a two-step process, starting from *exo*-norbornene anhydride. The anhydride was heated to reflux in toluene with 11-amino undecanoic acid for 12 h to get **3** as a pure white powder ([Figures S6 and S7](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The *S*-camptothecin was then reacted with **3** by using *N*,*N*′-dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP). The crude product was purified by column chromatography separation to get **Mono 2** as pure ([Figures [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b and [S8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). Toward the site-specific theranostic system, we synthesized norbornene functionalized with PEG--biotin (**Mono 3**). To attach the biotin moiety ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}), first, we prepared amine-terminated Nor-PEG (**7**). For that, we synthesized boc-protected glycin (**4**) ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). Boc anhydride was used to block the amine group of the glycin ([Figures S9 and S10](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The boc-protected glycin (1.05 equiv) was further reacted with PEG in tetrahydrofuran (THF) (1 equiv) (*M*~n~ = 650 Da) in the presence of DCC and DMAP, which gave the boc-protected amine-terminated PEG (**5**). This molecule was precipitated in cold hexane three times to get a white sticky material as product (**5**), which was confirmed by ^1^H NMR spectroscopy ([Figure S11](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The free −OH group present at the end of the PEG motif of compound **5** was functionalized to *exo*-norbornene carboxylic acid by using DCC and DMAP ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The product was precipitated in cold hexane to get boc-protected Nor-PEG amine (**6**) ([Figure S12](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The deprotection of Nor-PEG-amine boc (**6**) was done by using trifluoroacetyl in dichloromethane (DCM). The formation of product (**7**) was confirmed by the disappearance of the characteristics of boc methyl proton at δ = 1.39 ppm peak ([Figure S13](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). After the successful synthesis of the amine-terminated Nor-PEG (**7**), biotin was reacted to it by using DCC and DMAP ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}) to get **Nor-PEG-Btn** (**Mono 3**). The formation of the product was characterized by an ^1^H NMR spectrum ([Figure S14](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)), where the entire characteristic peaks appeared. MALDI-TOF analysis further supported the formation of the product ([Figure S18](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)).

After the successful synthesis of all monomers **(Mono 1--3)**, their polymerization conditions were explored. A series of homopolymers were produced by using Grubbs third-generation catalyst (G-3) with different feed ratios to evaluate the livingness of all monomers^[@ref24]^ ([Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"}). It was observed that the polymerizations were well-controlled ([Figures [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} and [S22](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)), resulting in a narrow polydispersity index (PDI), with a good yield (70--80%). After establishing the homopolymerization conditions for all monomers, triblock copolymerization was carried out by using Grubbs' third generation catalyst (G-3) at room temperature in an anhydrous DCM solvent by the sequential addition of **Mono 1--3** ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}a,b). The polymerization was monitored by ^1^H NMR spectroscopy. The molecular weights of **macro initiator 1** (*M*~n~ = 6000, PDI = 1.03), **macro initiator 2** (*M*~n~ = 21 000, PDI = 1.12), and the final triblock copolymer (**Pnr-Cbt-Cpt-Pg-Bn**, *M*~n~ = 39 000, PDI = 1.35) were measured in gel permeation chromatography (GPC) by using polymethyl methacrylate standards ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c). The shifting of GPC traces clearly indicated the formation of triblock copolymer (**Pnr-Cbt-Cpt-Pg-Bn**) ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c). The formation of the copolymer was confirmed by ^1^H NMR spectroscopy ([Figure S19](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)).

![a,b) Homopolymerization of **Mono 1--3** with different M/I ratios.](ao-2017-00221k_0002){#fig2}

![(a) A toolbox comprising the monomers (**Mono 1--3**). (b) Polymerization scheme of **Pnr-Cbt-Cpt-Pg-Bn**. (c) Gel permeation chromatogram of triblock copolymer **(Pnr-Cbt-Cpt-Pg-Bn)**. **Macro initiator 1 (Nor-Cob)***M*~n~ = 6000 Da (PDI = 1.03) (*m* = 12), **macro initiator 2 (Nor-Cob-Cpt)***M*~n~ = 22 000 Da (PDI = 1.12) (*n* = 19), and final triblock copolymer **(Pnr-Cbt-Cpt-Pg-Bn)***M*~n~ = 39000 Da, (PDI = 1.35) (*p* = 15).](ao-2017-00221k_0003){#fig3}

The final polymer was highly water soluble. The attachment of cobalt carbonyl to the terminal alkyne group was confirmed by IR spectrum ([Figure S17](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The IR spectrum of **2** showed a stretching frequency around 2126 cm^--1^ corresponding to the acetylene moiety, which completely disappeared, and three new bands were observed at 2097, 2056, and 2020 cm^--1^ corresponding to the metal-carbonyl group^[@ref22]^ ([Figure S17](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). After confirming the formation of **Pnr-Cbt-Cpt-Pg-Bn**, its thermal stability was measured by using thermogravimetric analysis (TGA) ([Figure S16](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). TGA of **Pnr-Cbt-Cpt-Pg-Bn** was performed at a heating rate of 10 °C/min under a nitrogen atmosphere. The first degradation point was observed at 220 °C ([Figure S16](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). It was also observed that around 25% of degradation clearly confirmed the degradation of the cobalt unit from the polymeric backbone, which was in agreement with the previously reported literature^[@ref28]^ and also confirmed the cobalt attachment to the polymer. Because of the complex architectural amphiphilicity of the nanotheranostic agent, it is expected that this will form a self-assembled aggregated structure in the polar aqueous solvent, where the hydrophobic unit cobalt and the drug will be inside of the core, whereas PEG will form the shell; therefore, dynamic light scattering (DLS) analysis was done in water to measure the size of the nanoaggregates.^[@ref27],[@ref29],[@ref30],[@ref32],[@ref33]^ The size (diameter) of the aggregates was found to be around 120 nm with 0.325 PDI ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}a). Thereafter, the morphology of the aggregate was checked by a scanning electron microscope. Because of the presence of Co^2+^ inside of the nanotheranostic agent, even without any contrast agent, the aggregates appeared dark under the electron beam ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b). The EDX experiment showed that all particular spherical micelles contained the cobalt unit ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}b), which proves our hypothesis. Thereafter, we checked the sustained release capability of CPT from **Pnr-Cbt-Cpt-Pg-Bn** nanotheranostic agent in acidic pH 5.2. The drug release kinetics of **Pnr-Cbt-Cpt-Pg-Bn** in 5% acetonitrile in phosphate-buffered saline (PBS, pH values 7.4 and 5.2) at room temperature were analyzed at an excitation wavelength of 360 nm at different time intervals.^[@ref38]^

![(a) DLS study of **Pnr-Cbt-Cpt-Pg-Bn**, (b) SEM and EDX analysis of **Pnr-Cbt-Cpt-Pg-Bn**, and (c) drug release study of **Pnr-Cbt-Cpt-Pg-Bn** in pH 7.4 and 5.2.](ao-2017-00221k_0004){#fig4}

At pH 5.2, around 72% of the drug was released, whereas at pH 7.4, the percentage of released drug was less than 5 ([Figure [4](#fig4){ref-type="fig"}](#fig4){ref-type="fig"}c), which proved the stability of the nanocarrier **(Pnr-Cbt-Cpt-Pg-Bn)** under physiological conditions.^[@ref39],[@ref40]^

Next, to prove the theranostic capability of the nanocarrier, an NMR 1D experiment of the nanocarrier (**Pnr-Cbt-Cpt-Pg-Bn**) was performed. All experiments were performed using a 500 MHz Avance-III Bruker spectrometer equipped with a linear gradient amplifier parallel to the static magnetic field.^[@ref31]^ Three sample solutions were prepared for a comparative study. A 1:5 mixture of H~2~O and D~2~O in v/v ratio was used as the common solvent for all three sample solutions. The contrast agent was added to the solvent to obtain concentrations of 0, 0.1, and 0.5 mM. The first solution (without any contrast agent, i.e., the 0 mM solution) was used as a reference. The sample solutions were poured in 5 mm quartz NMR tubes to obtain the MRI images.

The pulse sequence used to establish the efficiency of the contrast agent is a spin-echo-based sequence.^[@ref25]^ The sequence employs an acquisition under a linear gradient strength of 10 g/cm to obtain a *T*~2~-weighted 1D image of the sample. [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}a,b depict the pictorial representation of the pulse sequence and the Fourier spectrum. The echo period in the pulse sequence has been varied from 10 to 100 ms in steps to 10 ms. The Fourier transform of the acquired free induction decay collected under gradient yields a *T*~2~-weighted 1D image of the sample solution for various echo periods owing to the spatial encoding. A series of spectra indicates the rapidity with which the signal decreases. For a given concentration, the resulting spectra are plotted in a contour diagram for a spatial extension of 2 mm of the sample. All processing was performed using MATLAB software. The intensity of the acquired signal has been plotted in a descending color-scale of red to blue, where blue indicates a stronger signal compared with that of red ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c).

![(a,b) Pictorial representation of the pulse sequence and the Fourier spectrum. (c) Contour diagram in any of the subplot shows how quickly the signal decays from high intensity (red) to low intensity (blue).](ao-2017-00221k_0005){#fig5}

A contour diagram in any of the subplot of [Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c shows how quickly the signal decays from high intensity (red) to low intensity (blue). For the blank solution (0 mM), the signal nearly vanishes near 80 ms (the beginning of blue region), whereas the same behavior is observed at 50 and 30 ms for the 0.1 and 0.5 mM solutions, respectively ([Figure [5](#fig5){ref-type="fig"}](#fig5){ref-type="fig"}c). Thus, the contour diagram clearly indicates that the decay of the acquired signal strongly depends on the concentration of the nanotheranostic agent.

After confirming the MRI capability of the nanotheranostic agent **(Pnr-Cbt-Cpt-Pg-Bn)**, experiments at the cellular level were performed and compared with **free CPT** and the theranostic agent without being modified with biotin (**Pnr-Cbt-Cpt-Pg**) ([Scheme S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). For the in vitro cytotoxicity study, HeLa wt cells (human cervical cancer cell line) were maintained in minimum essential medium containing 10% fetal bovine serum, penicillium (100 U/mL), and streptomycin (100 μg/mL). It was incubated at 37 °C in a 5% CO~2~ environment according to American Type Culture Collection recommendations. Cells were seeded in 96-well plates at a density of 1 × 10^4^ cells per well and grown for 24 h.

Cells were exposed with serial dilutions of various drug concentrations in the media (25--500 μg/mL) of **Pnr-Cbt-Cpt-Pg-Bn** and **Pnr-Cbt-Cpt-Pg** at 37 °C. The cytotoxicity of the nanoaggregates **Pnr-Cbt-Cpt-Pg** and **free CPT** on HeLa wt cells were also assessed by the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyltetrazolium bromide (**MTT**) assay (5 mg/mL) in PBS. The **free CPT** was dissolved in 0.01% dimethyl sulfoxide (DMSO) in media. It is well-documented that because of the poor solubility of CPT, it is difficult to be applied in chemotherapy.^[@ref12]^ Although different analogues of CPT have been synthesized by different research groups, cytotoxicity has been tested by dissolving the moieties exclusively in DMSO.^[@ref34]^ However, DMSO by itself is toxic toward various cell lines and thus to living systems.^[@ref37]^ Because of the hurdles, the PEG-modified CPT has only reached clinical trials.^[@ref12],[@ref35],[@ref36]^ Thus, testing the therapeutic activity of a drug by dissolving it in DMSO alone will not provide the actual therapeutic benefits. Because HeLa wt cell lines are used to test the cytotoxicity of both the controls (**free CPT** and the **nanocarriers**), an already reported quantity of 0.01% DMSO was used, as it is not toxic to the cells at this quantity.^[@ref37]^ Because of the presence of PEG, our nanocarrier is soluble in biological media. However, to show a more pronounced effect of the nanocarrier in comparison with the **free CPT**, the cytotoxicity experiment for CPT was carried out in 0.01% DMSO in media, whereas for the nanocarrier, the experiment was exclusively carried out in biological media (no DMSO). This can correlate the solubility factor as a nominal amount of DMSO was added and hence can provide insight into the usefulness of the aqueous solubility of chemotherapeutic agents. Even the water-soluble CPT analogue topotecan·HCl has been given approval for the treatment of cervical cancer.^[@ref41]^

The incubation time for each was 24 h. Although the cytotoxicity experiment for CPT was done in 0.01% DMSO in media, **free CPT** was still suffering from poor solubility. Hence, the undissolved part was filtered, and in vitro studies were done with the remaining solution. The concentration of **free CPT** was calculated from the amount of CPT soluble in the stock solution, and different concentrations of CPT solutions were prepared from the stock solution to perform the MTT assay. Further, to understand the cytotoxic nature of biotin-modified nanocarrier (**Pnr-Cbt-Cpt-Pg-Bn)** because of the enhanced internalization through receptor-mediated endocytosis, the PEG modified nanocarrier (**Pnr-Cbt-Cpt-Pg**) was used as a control molecule to compare the effects ([Scheme S2](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)).

A fresh 20 μL solution of **MTT** was added to each well, followed by incubation for 4 h in 5% CO~2~ at 37 °C. The medium in each well was removed, and 100 μL of DMSO was added to each well and agitated for 15 min. The absorbance of the purple solution was measured at 525 nm by the enzyme-linked immunosorbent (immunoadsorbant) assay (ELISA) plate reader (BioTek Instrument---ELx 800). The killing efficiency was prominent in the case of **Pnr-Cbt-Cpt-Pg-Bn** compared with **free CPT** and **Pnr-Cbt-Cpt-Pg** ([Figure [6](#fig6){ref-type="fig"}](#fig6){ref-type="fig"}a,b). This can be attributed to the mechanism of receptor-mediated endocytosis, as **Pnr-Cbt-Cpt-Pg-Bn** can be easily internalized by the cancer cell through a biotin receptor, which is missing in the case of **Pnr-Cbt-Cpt-Pg** and **free CPT**. In addition, the higher uptake of **Pnr-Cbt-Cpt-Pg** by the cancer cells in comparison with the **free CPT** can be attributed to the solubility factor.

![(a) Comparative cell viability assay of **Pnr-Cbt-Cpt-Pg**, **Pnr-Cbt-Cpt-Pg-Bn**, and (b) **free CPT** (partially soluble in 0.01% DMSO in media) on HeLa wt cell lines.](ao-2017-00221k_0006){#fig6}

To further investigate the biotin-assisted internalization, cellular uptake studies of **Pnr-Cbt-Cpt-Pg-Bn** were explored and compared with **Pnr-Cbt-Cpt-Pg** and **free CPT** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}). **Pnr-Cbt-Cpt-Pg-Bn** could rapidly enter owing to the incorporated biotin group, which showed an excellent cell-penetrating activity to promote cell internalization compared with **Pnr-Cbt-Cpt-Pg** ([Figure [7](#fig7){ref-type="fig"}](#fig7){ref-type="fig"}), whereas **free CPT** suffering from aqueous solubility could not show a pronounced effect.

![Comparative cellular uptake of **free CPT (partially soluble in 0.01% DMSO in media**) and **Pnr-Cbt-Cpt-Pg** and **Pnr-Cbt-Cpt-Pg-Bn** nanocarriers on HeLa wt cell lines.](ao-2017-00221k_0007){#fig7}

This was further confirmed by flow cytometry analysis, which shows about a 2 times higher uptake of nanocarriers (**Pnr-Cbt-Cpt-Pg-Bn**) in HeLa wt cell lines compared with **Pnr-Cbt-Cpt-Pg** at the same concentration ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}), whereas for **free CPT**, the mean intensity value is lower than that of both the nanocarriers **Pnr-Cbt-Cpt-Pg-Bn** and **Pnr-Cbt-Cpt-Pg**, which can be attributed to the solubility factor ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).

![Flow cytometry analysis of **free CPT** and **Pnr-Cbt-Cpt-Pg** and **Pnr-Cbt-Cpt-Pg-Bn** nanocarriers on HeLa wt cell lines.](ao-2017-00221k_0008){#fig8}

The lower uptake of **Pnr-Cbt-Cpt-Pg** to the cancer cell lines (HeLa wt) compared with **Pnr-Cbt-Cpt-Pg-Bn** can be attributed to the presence of a receptor on the cancer cell surface and not on the normal cell surface and that makes our system site-specific as the nanocarrier follows the receptor-mediated endocytosis ([Figure [9](#fig9){ref-type="fig"}](#fig9){ref-type="fig"}).^[@ref3]^ However, the **free CPT**, which is suffering from the solubility issues, shows the lowest uptake compared with nanocarriers **(Pnr-Cbt-Cpt-Pg-Bn** and **Pnr-Cbt-Cpt-Pg)** ([Figure [8](#fig8){ref-type="fig"}](#fig8){ref-type="fig"}).

![Cartoon representation of site-specific delivery of **Pnr-Cbt-Cpt-Pg-Bn**.](ao-2017-00221k_0009){#fig9}

Conclusions {#sec4}
===========

This paper describes the synthesis of a unique cell-internalizable stimuli-responsive nanotheranostic agent for the purpose of MRI and drug-delivery application. The well-shielded therapeutic agent CPT into the polymeric micelle shows excellent triggered release of CPT in response to intracellular pH that enhances the therapeutic efficacy as well as reduces the cytotoxic effect. The covalently bound paramagnetic cobalt block stabilized inside the core of the micelle shows excellent *T*~2~ relaxation properties in very low concentration. Further, owing to the presence of the biotin moiety, the nanothernostic agent shows a higher cellular uptake compared with **free CPT** and **Pnr-Cbt-Cpt-Pg**, which is the crucial characteristic of a nanotheranostic agent in site-specific cancer therapy. Thus, this molecule is expected to play a crucial role in theranostics.

Experimental Section {#sec5}
====================

Synthesis of **Mono 1** {#sec5-1}
-----------------------

In an anhydrous two-neck round bottomed flask, **2** (0.8 g, 0.001586 mol) was dissolved in anhydrous DCM. N~2~ gas was passed through the solution, and the flask was kept in an ice bath. In another flask, cobalt carbonyl (1.1 g, 0.00317 mol) was dissolved in anhydrous DCM. This was added in a dropwise fashion to the solution containing **2**. After that, the reaction mixture was stirred for 2 h in room temperature. After the completion of the reaction (monitored by TLC), the solvent was removed under vacuum. The product was recovered by precipitating it from pentane. The pure product was collected by column chromatography separation process. (SiO~2~, DCM, acetone). Yield: 0.63 g (0.00142 mol, 90%). ^1^H NMR (CDCl~3~, 500 MHz) δ (ppm): 6.5 (s, 2H), 5.2 (s, 2H), 4.8 (s, 2H), 2.9 (s, 2H), 6.0 (s, 1H) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}a). ^13^C NMR (CDCl~3~, 500 MHz) δ (ppm): 200, 175, 136, 88, 81, 72, 47, 41 ([Figure S5](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). ESI MS calculated for C~19~H~15~Co~2~NO~9~ \[M + H\]^+^, 520.19; observed, 520.21.

Synthesis of **Mono 2** {#sec5-2}
-----------------------

**1** (250 mg, 0.72 mmol) was dissolved in anhydrous dimethylformamide (DMF), and DCC (178 mg, 0.86 mmol) was added to it. The reaction mixture was stirred for 1 h of (*S*)-camptothecin (225 mg, 0.64 mmol) and DMAP (9 mg, 0.072 mmol) were added to it. The reaction mixture was stirred for 24 h. After the completion of the reaction (monitored by TLC), the solvent was evaporated to dryness. A pure product was obtained by the column chromatographic separation method in the DCM:MeOH medium. Yield = 268 mg (0.039 mmol, 55%) ^1^H NMR (DMSO-*d*~6~, 500 MHz) δ (ppm): 8.7 (s, 1H), 8.1 (m, 1H), 7.8 (t, 1H), 7.7 (t, 1H), 7.3 (s, 1H), 6.5 (s, 1H), 6.25 (d, 2H), 5.42 (s, 2H), 5.28 (s, 2H), 3.9 (t, 2H), 3.08 (s, 2H), 2.67 (s, 2H), 2.2 (t, 2H), 1.2--1.7 (br s, 23H) ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}b). ^13^C NMR (CDCl~3~, 500 MHz) δ (ppm): 177, 172.5, 169.5, 156.8, 153.7, 152.5, 149.9, 148, 145.5, 137.5, 131.5, 130.3, 129.8, 129, 128.5, 127.9, 127.6, 118, 97, 72, 64, 52.5, 50.2, 49.5, 47.4, 47.2, 44.5, 42.2, 37.8, 34.5, 33.9, 33.3, 31.6, 30.3, 29, 28.5, 27.1, 26.3, 25.4, 25.3, 24.8 ([Figure S8](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)).

Synthesis of **Mono 3** {#sec5-3}
-----------------------

[d]{.smallcaps}-Biotin (0.1 g, 0.0004 mol) was dissolved in anhydrous DMSO, and DCC (0.126 g, 0.00061 mol) was added to it. The reaction mixture was stirred vigorously for 1 h. Then **11** (0.316 g, 0.00038 mol) was added to the reaction mixture along with the DMAP (3 mg, 0.0000226 mol). The reaction mixture was stirred vigorously for 24 h at room temperature. After the completion of the reaction, the reaction mixture was precipitated from cold diethyl ether. The precipitate was redissolved in the DCM:MeOH mixture and again reprecipitated in diethyl ether three times to get **Mono 3**. Yield: 260 mg (0.00024 mol, 60%). ^1^H NMR (DMSO-*d*~6~, 500 MHz) δ (ppm): ^1^H NMR (DMSO-*d*~6~, 500 MHz): 8.2 (d, 1H), 6.9 (d, 1H) 6.2 (d, 2H), 4.59 (t, 2H), 4.43--4.4 (m, 2H), 3.6 (s, broad), 2.9 (s, 2H), 2.19--2.28 (m, 2H), 2.30--2.33 (t, 2H), 2.0--2.07 (m, 2H), 1.86--1.94 (m, 2H), 1.50--1.56 (m, 2H), 1.2--1.6 (m, 2H) ([Figure S14](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). The formation of the product was also confirmed by MALDI analysis ([Figure S18](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)).

Preparation of Grubbs' Third Generation Catalyst {#sec5-4}
------------------------------------------------

Freshly prepared Grubbs' third generation catalyst^[@ref23]^ was used for all polymerization reactions. The desired amount of Grubbs' second generation catalyst (G-2) was placed in a glass vial. To this, 2-bromopyridine was added and stirred for 2 min. The immediate green coloration of the reaction mixture confirmed the formation of the catalyst. The product was precipitated from pentane. The whole reaction was carried out inside of the glove box under the nitrogen atmosphere.

Polymerization Procedure {#sec5-5}
------------------------

Polymerization was carried out by following previously reported literature.^[@ref21]−[@ref23]^ In general, a desired amount of Grubbs' third generation catalyst was added to each vial containing three monomers (**Mono 1--3**). Polymerization was carried out inside of the glove box under the nitrogen atmosphere.

The catalyst (3.5 mg) was transferred to the vial containing **Mono 1** (30 mg, 0.057 mmol) via a syringe. The reaction was allowed to stir for 10 min to complete polymerization. An aliquot of the sample was quenched with ethyl vinyl ether, precipitated in pentane, and taken for GPC analysis. GPC was done in THF (flow rate = 1 mL/min). The molecular weight of **macro initiator 1 (Nor-Cob)** was measured as *M*~n~ = 6000 Da (PDI = 1.04) by using polymethyl methacrylate standard. Then, the second monomer (**Mono 2**) (115 mg, 0.17 mmol) was added to the reaction vial after dissolving it in a minimum quantity of anhydrous CH~2~Cl~2~. The reaction mixture was stirred for 8 h, and an aliquot was taken for GPC analysis. The molecular weight of **macro initiator 2 (Nor-Cob-Cpt)** was measured to be *M*~n~ = 18 000 Da (PDI = 1.13) by using polymethyl methacrylate standard. Finally, **Mono 3** (1.5 g, 1.45 mmol) was added to the reaction vial and stirred until polymerization was completed. Then, the reaction mixture was quenched with ethyl vinyl ether (1 mL). An aliquot was taken for GPC analysis, and the remaining product was precipitated from pentane, dissolved again in THF, passed through neutral alumina to remove the catalyst, and precipitated again from pentane to get a pure triblock copolymer (**Pnr-Cbt-Cpt-Pg-Bn**). The molecular weight of the final triblock copolymer was measured as *M*~n~ = 39 000 Da, PDI = 1.34 ([Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"}c). The formation of the copolymer (**Pnr-Cbt-Cpt-Pg-Bn**) was further confirmed by ^1^H NMR spectroscopy ([Figure S19](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf)). After successful synthesis of **Pnr-Cbt-Cpt-Pg-Bn**, the THF solution of the copolymer was passed through a neutral alumina column, and the precipitation was done in diethyl ether three times. Then, the resulting polymer (**Pnr-Cbt-Cpt-Pg-Bn**) was dialyzed against the THF/water (3:1) mixture for 1 day by using a dialysis membrane (cut off *M*~n~ = 3500 Da).

The Supporting Information is available free of charge on the [ACS Publications website](http://pubs.acs.org) at DOI: [10.1021/acsomega.7b00221](http://pubs.acs.org/doi/abs/10.1021/acsomega.7b00221).Experimental section and NMR characterization of all monomers, TGA data of **Pnr-Cbt-Cpt-Pg-Bn**, IR data, MALDI, NMR, and GPC characterization of polymers, and percentage of attachment ([PDF](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b00221/suppl_file/ao7b00221_si_001.pdf))
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